Completed NA INTERVENTIONAL 2-arm NCT01272817

Nonmyeloablative Allogeneic Transplant (Mini-allo)

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation

Sponsor: Scripps Health

Conditions Acute Lymphocytic Leukemia Acute Myelogenous Leukemia Aplastic Anemia Breast Cancer Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia Hodgkin's Lymphoma Mantle Cell Lymphoma Melanoma Multiple Myeloma Myelodysplastic Syndrome Non-Hodgkin's Lymphoma Ovarian Cancer Paroxysmal Nocturnal Hemoglobinuria Renal Cell Carcinoma Sarcoma Thymoma Waldenstrom Macroglobulinemia

Interventions Nonmyeloablative Allogeneic Transplant

Updated 6 times since 2017 Last updated: Nov 21, 2022 Started: Oct 31, 2001 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Acute Lymphocytic Leukemia and Acute Myelogenous Leukemia, this trial is completed. The trial is conducted by Scripps Health and has accumulated 6 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Dec 2022 — Jul 2024 [monthly]

Completed NA

Status: Unknown Status → Completed
Jan 2021 — Dec 2022 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Scripps Health

Data source: Scripps Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• La Jolla, United States